[Translation] Human bioequivalence clinical trial of octopaine capsules in healthy Chinese populations under fasting and postprandial conditions with a single dose.

主要目的：以持证商为Amneal Pharmaceuticals LLC的奥匹卡朋胶囊（商品名：Ongentys，规格：25mg）为参比制剂，以南京海纳制药有限公司研发的奥匹卡朋胶囊（25mg）为受试制剂，评价两种制剂在中国健康试验参与者中空腹和餐后状态下的生物等效性。次要目的：观察受试制剂和参比制剂在中国健康试验参与者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of octopaine capsules (trade name: Ongentys, strength: 25mg) manufactured by Amneal Pharmaceuticals LLC as the reference formulation and octopaine capsules (25mg) developed by Nanjing Haina Pharmaceutical Co., Ltd. as the test formulation in healthy participants in a Chinese trial, under fasting and postprandial conditions. Secondary objective: To observe the safety of the test and reference formulations in healthy participants in a Chinese trial.

Start Date25 Aug 2026

Sponsor / Collaborator

Nanjing Healthnice Pharmaceutical Co., Ltd.

CTR20261722

/ CompletedNot Applicable

奥吡卡朋胶囊在健康试验参与者中的单剂量、空腹、随机、开放、两周期、两交叉生物等效性研究

[Translation] A single-dose, fasting, randomized, open-label, two-period, two-crossover bioequivalence study of opiacapone capsules in healthy trial participants.

主要研究目的：以四川科伦药业股份有限公司生产的奥吡卡朋胶囊（50 mg）为受试制剂，Bial-Portela & Ca.S.A.持证并生产的奥吡卡朋胶囊（50mg，商品名：ONGENTYS®）为参比制剂，比较受试制剂和参比制剂在空腹条件下单次给药后的生物等效性。次要研究目的：观察受试制剂和参比制剂在单次给药后试验参与者中的安全性。

[Translation]

Primary objective: To compare the bioequivalence of the test formulation and the reference formulation after a single dose under fasting conditions, using opipalacon capsules (50 mg) manufactured by Sichuan Kelun Pharmaceutical Co., Ltd. as the test formulation and opipalacon capsules (50 mg, trade name: ONGENTYS®) manufactured by Bial-Portela & Ca.S.A. as the reference formulation. Secondary objective: To observe the safety of the test formulation and the reference formulation in participants after a single dose.

Start Date01 Jun 2026

Sponsor / Collaborator

Sichuan Kelun Pharmaceutical Co., Ltd.

CTR20260993

/ CompletedNot Applicable

奥吡卡朋胶囊在空腹条件下的人体生物等效性研究

[Translation] Bioequivalence study of opiacarpon capsules in humans under fasting conditions

主要研究目的研究空腹状态下单次口服受试制剂奥吡卡朋胶囊与参比制剂奥吡卡朋胶囊（Ongentys ®）在健康成年试验参与者体内的药代动力学，评价空腹状态下口服两种制剂的生物等效性。次要研究目的研究受试制剂奥吡卡朋胶囊和参比制剂“Ongentys®”在健康试验参与者中的安全性。

[Translation]

Primary Study Objective: To investigate the pharmacokinetics of a single oral dose of the test formulation opiporone capsules and the reference formulation opiporone capsules (Ongentys®) in healthy adult participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions. Secondary Study Objective: To investigate the safety of the test formulation opiporone capsules and the reference formulation Ongentys® in healthy participants.

Start Date23 Mar 2026

Sponsor / Collaborator

Qilu Pharmaceutica Hainanco Ltd.

100 Clinical Results associated with Opicapone

100 Translational Medicine associated with Opicapone

100 Patents (Medical) associated with Opicapone

178

Literatures (Medical) associated with Opicapone

31 Dec 2026·ANNALS OF MEDICINE

Advanced Parkinson’s disease treatment patterns in Italy: results from a multicenter observational study

Article

Author: Modugno, Nicola ; Ceravolo, Roberto ; Stocchi, Fabrizio ; De Pandis, Maria Francesca ; Barone, Paolo ; Padovani, Alessandro ; Lopiano, Leonardo ; Tessitore, Alessandro ; Zappia, Mario ; Pilleri, Manuela

BACKGROUND AND OBJECTIVES:

Substitution therapy with oral levodopa is the primary treatment of Parkinson's disease (PD). However, long-term levodopa use is associated with fluctuations in response and dyskinesia. These complications severely affect the patient quality of life. Fluctuation management in long-standing PD is poorly documented. The Parkinson's Disease Fluctuations treatment Pathway (PD-FPA) study was an Italian multicenter, observational study designed to describe how fluctuations are treated in patients with advanced disease.

PATIENTS AND METHODS:

Between July 2018 and December 2020, ten centres enrolled consecutive patients aged ≥18 years who had been diagnosed with PD 10-15 years before enrollment and had been experiencing fluctuations for at least 2 years before enrollment. Data on patient characteristics, PD stage, fluctuations, and treatments were collected at enrollment (T0) and prospectively at 6 months (T1) and 12 months (T2). Data were also collected retrospectively, at 1 and 2 years before T0.

RESULTS:

At T0, patients (n = 296, 60.1% male, mean age 68 years) had Hoehn and Yahr disease stage 2-3 and 47% had comorbidities (29.8% cardiovascular disease). PD stage and other PD assessment scores were overall stable during the entire 3-year observation period. Over 3 years, the use of dopamine agonists progressively decreased (51% of patients at T2), the use of monoamine oxidase-B inhibitors was stable (63%), while the use of catechol-O-methyltransferase inhibitors progressively increased (42%). Safinamide and opicapone showed the biggest increase in use over the 3-year observation period. Treatment changes were mostly prompted by fluctuations and were reported in about 50% of patients at T0 and 30% at T1 and T2.

CONCLUSION:

Maintenance of stable disease in patients with long-standing PD and fluctuations is feasible with non-invasive treatments. Accurate treatment adjustments and individualized strategies with new-generation add-on drugs may be of key importance.

01 Aug 2026·DRUGS

Recent Developments in the Drug Treatment of Parkinson’s Disease

Review

Author: Leiter, Simon ; Mahlknecht, Philipp ; Poewe, Werner

Parkinson's disease (PD) is a common neurodegenerative disorder caused by a spread of misfolded α-synuclein and ascending neuronal degeneration mainly in dopaminergic neurons, leading to progressive nigrostriatal dysfunction and disruption of other pathways. It is clinically defined by its cardinal motor features of bradykinesia, rest tremor and rigidity, which are usually accompanied by a variety of non-motor symptoms. Here we provide a review on recent developments in the pharmacological treatment of PD with a focus on recently approved drugs, new modes of delivery and agents that are in advanced stages of clinical development. Pharmacological dopamine substitution remains the mainstay of symptomatic treatment approaches to control PD motor symptoms. While levodopa is still considered the gold-standard of symptomatic efficacy, its chronic use is associated with the development of response oscillations and drug-induced dyskinesias in a majority of patients. Thus, much effort has been put into developing more continuous ways of levodopa delivery. Novel formulations and modes of application include extended-release (ER) oral levodopa (IPX203), levodopa powder for inhalation, and levodopa infusion therapies through subcutaneous (foslevodopa/foscarbidopa, ND0612) or intrajejunal pumps (levodopa [entacapone] carbidopa intestinal gel). Additionally, different preparations for subcutaneous and sublingual administration of apomorphine, a dopamine agonist with equivalent efficacy to levodopa, are available for the treatment of PD motor fluctuations. Novel dopamine agonists have been developed and tavapadon, a selective dopamine D1/D5 receptor partial agonist, was shown to be efficacious as monotherapy in early PD and adjunct to levodopa in patients with motor fluctuations. In addition, new data on the early use of the COMT-inhibitor opicapone have emerged. This expanding drug armamentarium is complemented by an increasing number of drugs targeting non-dopaminergic pathways with increasing evidence for amantadine's symptomatic efficacy in treating levodopa-induced dyskinesia and motor fluctuations. Beyond the approval of different botulinum toxin preparations for the treatment of sialorrhea, efforts to address the plethora of non-motor symptoms of the disease have not translated to novel PD-specific approvals over the last few years. PD symptoms can usually be satisfactorily controlled in the early to mid-stages, but the progressive course of the disease inevitably leads to increasing functional disability underlining the yet unmet need for disease-modifying therapies. While there is currently no conclusive evidence for disease-modifying efficacy on any of the numerous efforts, we summarize recent late-stage clinical trial evidence focusing on glucagon-like peptide 1 (GLP1) agonists, approaches targeting the glucocerebrosidase (GBA) pathway and inhibition of the leucine-rich repeat kinase 2 (LRRK2), as well as α-synuclein based treatments.

01 Jun 2026·Journal of Parkinsons Disease

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations

Article

Author: Holenz, Joerg ; Brigas, Helena C. ; Fonseca, Miguel M. ; Antonini, Angelo ; Poewe, Werner ; Rascol, Olivier ; Stocchi, Fabrizio ; Ferreira, Joaquim J. ; Rocha, José-Francisco ; Moreira, Joana

Primary results from the 24-week EPSILON study (NCT04978597) showed that adding opicapone to levodopa in non-fluctuating Parkinson's patients significantly improved motor impairment without increasing the development of motor complications versus placebo. All participants finishing the double-blind phase became eligible for open-label treatment with opicapone. Symptomatic efficacy of opicapone was maintained with 1-year open-label treatment (adjusted-mean ± SE change in MDS-UPDRS motor score from double-blind baseline to Week 76: −7.4 ± 0.81); participants who switched from placebo to opicapone had a motor improvement of −6.1 ± 0.79. At Week 76, 80.2% of opicapone-opicapone-treated participants remained motor complication-free versus 69.7% in the placebo-opicapone group (p = 0.1).

News (Medical) associated with Opicapone

09 Jun 2026

·www.fiercebiotech.com

Bial bails after Parkinson’s fail, axing asset over phase 2 miss

The mechanism of action suggested BIA 28-6156 could be a disease-modifying therapy.\n Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints. Portugal-based Bial designed the study to compare BIA 28-6156 to placebo in 273 Parkinson\'s patients with a pathogenic variant in the GBA1 gene. People in the treatment arms received one of two doses of BIA 28-6156, a molecule that activates the GCase enzyme to restore lipid metabolism and lysosomal function. Studies have linked compromised GCase activity to the decline of Parkinson’s patients.While the mechanism of action suggested BIA 28-6156 could be a disease-modifying therapy, the phase 2b failed to generate evidence that the molecule improves outcomes. The primary endpoint looked at the time to clinically meaningful progression on motor aspects of experiences of daily living.The study missed its primary endpoint. And with BIA 28-6156 also performing no better than placebo on key secondary endpoints, Bial has ended development of the drug candidate in the trial population. Bial is running one other BIA 28-6156 study, which is evaluating the molecule in people with varying degrees of renal impairment. Bial has yet to share data from the failed phase 2b trial, saying only that the study missed its key efficacy endpoints but found BIA 28-6156 to be generally well tolerated. No unexpected safety concerns were seen, Bial said. The drugmaker plans to share data from the trial through peer-reviewed publications and scientific meetings.Pulling back from BIA 28-6156 blows a hole in Bial’s R&D pipeline. Beyond BIA 28-6156, the company is only running non-interventional studies of opicapone and a sublingual apomorphine formulation. Both trials are enrolling Parkinson’s patients. Bial acquired the European rights to a sublingual apomorphine drug, Kynmobi, in 2021. The company won European approval for opicapone, sold as Ongentys, in 2016.

Phase 2Drug ApprovalClinical ResultOligonucleotide

09 Jun 2026

·allsci.com

Bial ends development of GCase activator pariceract in Parkinson’s after Phase II fail

Portugal-based Bial reported that pariceract (BIA 28-6156; formerly LTI-291, LTI-00291), its oral small-molecule allosteric activator of beta-glucocerebrosidase (GCase), failed to slow disease progression in patients with GBA1 gene-associated Parkinson’s disease, ending development of what had been one of the few mechanism-specific candidates in this genetically defined population. The result closes a program that had enrolled 273 patients across 85 sites in Europe and North America, and deals a further setback to the GCase activation hypothesis in GBA-associated Parkinson’s disease — a subtype affecting an estimated 5%-15% of all Parkinson’s patients and typically characterized by faster motor progression and earlier cognitive decline than idiopathic disease. The ACTIVATE trial was a Phase IIb, multicenter, randomized, double-blind, placebo-controlled study evaluating pariceract in genetically confirmed GBA-PD patients across two fixed oral doses (10 mg/day and 60 mg/day). Enrollment of 273 patients took approximately 18 months, with sites spanning 11 countries. The study assessed efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics. Bial announced the first patient to complete the full dose regimen in January 2025, with topline data expected mid-2026. Neither the primary endpoint nor the key secondary efficacy endpoints were met. Bial did not disclose the specific primary endpoint measure or numerical efficacy data in the topline release, stating only that pariceract “failed to slow the progression of GBA-PD versus placebo”. The drug was reported as generally well tolerated, with no unexpected safety concerns identified — a finding that does not rescue the program but may inform future mechanistic work in the field. Based on the absence of demonstrated efficacy, Bial has discontinued further development of pariceract for this indication. Competitive context The GCase activation space has now accumulated two high-profile clinical failures in rapid succession. In May 2026, Biogen (Nasdaq: BIIB) and Denali Therapeutics (Nasdaq: DNLI) reported that BIIB122 (DNL151), a small-molecule LRRK2 inhibitor, failed its Phase IIb LUMA study in early-stage idiopathic Parkinson’s disease — a different target but another genetically informed disease-modification strategy that did not translate into clinical benefit. While the LUMA failure involved a distinct mechanism and broader patient population, it reinforces the difficulty of demonstrating disease modification in Parkinson’s with current trial designs and endpoints. Within the GCase space specifically, competitors remain active at earlier stages. Maryland-based Gain Therapeutics (Nasdaq: GANX) is advancing GT-02287, a GCase allosteric modulator, in a Phase Ib extension study in patients with Parkinson’s disease with or without a GBA1 mutation. Interim data presented in May 2026 showed stable MDS-UPDRS scores over 150 days and a differential response pattern in patients with elevated baseline cerebrospinal fluid glucosylsphingosine, a GCase substrate biomarker — though the study was not designed to assess clinical efficacy. Chicago-based Vanqua Bio reported Phase Ib data in March 2026 showing that VQ-101, another oral GCase activator, achieved greater than 50% activation of lysosomal GCase in GBA-Parkinson’s patients, meeting a pre-specified target engagement goal. Both programs remain substantially earlier in development than pariceract was at the time of its failure. Cross-trial comparisons are limited by differences in patient populations, dose levels, trial duration, and endpoint selection, and the mechanistic success of earlier-stage programs does not predict Phase II outcomes. The pariceract result will prompt scrutiny of whether GCase target engagement alone — without demonstrated downstream effects on alpha-synuclein aggregation or neurodegeneration — is sufficient to support efficacy hypotheses in GBA-PD clinical trials. The failure also raises questions about trial design in this space. GBA-PD patients progress faster than idiopathic PD patients on average, which theoretically improves statistical power to detect disease modification over a given timeframe. Whether the ACTIVATE study was adequately powered, whether the doses selected achieved sufficient central nervous system GCase activation, and whether the primary endpoint was sensitive enough to detect clinically meaningful slowing will be central questions when Bial presents full data at scientific meetings. The company said it intends to disseminate the ACTIVATE data through peer-reviewed publications and conferences. For Bial, which invests over 20% of annual revenue in R\&D and has focused its neuroscience pipeline on Parkinson’s disease, the discontinuation removes what had been a lead disease-modification asset. The company’s approved portfolio includes opicapone (Ongentys), a COMT inhibitor used as adjunct therapy to levodopa in Parkinson’s patients with motor fluctuations — a symptomatic treatment that competes in a different segment of the disease management landscape. Pariceract had represented Bial’s attempt to move upstream toward disease modification in a genetically defined subpopulation, a strategy that now requires reassessment. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Clinical ResultPhase 2Phase 1

26 May 2026

·www.biospace.com

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s

Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress PORTO, Portugal--(BUSINESS WIRE)-- #BIA28 --Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3 rd International GBA1 Meeting 2026 . The team is currently attending the 7 th World Parkinson Congress , taking place in Phoenix from 24 to 27 May 2026. “Momentum is building across the Parkinson’s scientific community around the clinical potential of pariceract. At the GBA1 Meeting and the 7th World Parkinson Congress , we have been able to connect with this community as we approach a key milestone, the anticipated release of topline results from our ACTIVATE study," said Raquel Costa, Head of Clinical Operations and study lead. 273 genetically confirmed GBA-PD patients were enrolled over approximately 18 months across 85 clinical sites in 11 countries throughout Europe and North America. The study reported strong patient retention, reflecting the commitment of patients and study site teams. “This is a particularly exciting moment for the whole Parkinson’s community and for Bial. We would like to sincerely thank the patients, their families, investigators, and site teams who contributed to the ACTIVATE with extraordinary commitment and rigour over the course of the study. We are hopeful that BIA 28-6156 may help address a major unmet need by targeting the underlying cause of GBA1-associated Parkinson’s," added Raquel Costa. The ACTIVATE study is evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with GBA-PD. BIA 28-6156 is in development as a first-in-class, small molecule for once-daily oral administration, allosteric activator of beta-glucocerebrosidase (GCase), for the treatment of patients with GBA-PD. By increasing the activity of GCase, BIA 28-6156 may be the first drug to directly modify the underlying cause of the disease in this group of patients by re-establishing the sphingolipid recycling. (1,2) Parkinson’s is the second most common neurodegenerative disorder, affecting more than 10 million people worldwide. (3) Between 5-15% of Parkinson’s patients have mutations in the GBA1 gene, making it the largest genetic risk factor. (4) GBA-PD patients tend to have, on average, an earlier onset of symptoms compared to those with idiopathic Parkinson’s (5) and have more severe clinical symptoms that progress significantly faster, leading to a worse overall prognosis, (4) thus emphasising the importance of developing new treatments for this condition. Translating Bial’s focus on Parkinson's Disease research and development, the company is also presenting two posters at the 7 th World Parkinson Congress, highlighting patient perspectives on treatment routines and adherence, and new insights from a Phase IV study on opicapone’s effects on sleep and non-motor symptoms in Parkinson’s. Posters Details: Date: 26 May 2026 Session Time: 11:30 AM - 1:00 PM Location: Room: Hall D-E (3rd floor) - Phoenix Convention Center Posters Title: TRACK-PD: Understanding Treatment Routines and Adherence in Care - Knowledge and Perspectives of People Living with Parkinson’s Disease Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial About Bial Bial is an innovation-driven pharmaceutical company dedicated to improving the health and lives of people worldwide. With a strong commitment to therapeutic innovation, Bial has established an ambitious R&D programme, consistently investing over 20% of its annual revenue in this area. The company focuses on two key areas with high unmet medical needs: neurosciences and rare diseases. In Europe, Bial operates manufacturing facilities and a R&D centre at its headquarters in Portugal, and maintains affiliates in Spain, Germany, the United Kingdom, Italy, and Switzerland. In addition, Bial is present in the United States and selected emerging markets. As part of its international growth strategy, the company collaborates with established partners through strategic alliances and licensing agreements to expand access to its healthcare solutions. Currently, Bial’s products are available in more than 50 countries, advancing its mission to pursue scientific excellence, mainly in neurosciences and rare diseases, delivering transformative medicines that empower patients’ lives. For more information about BIA 28-6156, please visit: For more information about the trial design, please visit: (identifier: NCT05819359) For more information about Bial, please visit: References den Heijer JM et al. Br J Clin Pharmacol. 2021 Sep;87(9):3561-3573 Guedes L. et al. Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase). Presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Copenhagen, Denmark. August 27–31, 2023 APDA, , accessed May 18 th 2026 Smith L, Schapira AHV. Cells. 2022 Apr 8;11(8):1261 Gan-Or Z, et al. Neurology. 2015 Mar 3;84(9):880-7 Contacts Media Contacts: Bial Susana Vasconcelos Director, Communication T. +351229866100 | E. susana.vasconcelos@bial.com

Phase 2Phase 1

100 Deals associated with Opicapone

External Link

KEGG	Wiki	ATC	Drug Bank
D10825	Opicapone	N04BX04	DB11632

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinson Disease	European Union	BIAL-Portela & Cia SA	24 Jun 2016
Parkinson Disease	Iceland	BIAL-Portela & Cia SA	24 Jun 2016
Parkinson Disease	Liechtenstein	BIAL-Portela & Cia SA	24 Jun 2016
Parkinson Disease	Norway	BIAL-Portela & Cia SA	24 Jun 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Parkinson's disease	Phase 3	China	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	17 Apr 2023
Primary Parkinson's disease	Phase 3	China	BIAL-Portela & Cia SA	17 Apr 2023
Young onset Parkinson disease	Phase 3	Bulgaria	BIAL-Portela & Cia SA	31 May 2021
Parkinsonian Disorders	Phase 1	-	BIAL-Portela & Cia SA	01 Mar 2014
Epilepsy	Phase 1	-	BIAL-Portela & Cia SA	01 Feb 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EAN2026	Not Applicable	Parkinson Disease	104	Opicapone (60–75 years)	ypswwegdjf(fakdvpjmqn) = ufuxqoctra ohovakytap (hxpltdfaun )	Positive	26 Jun 2026
				Opicapone (≥75 years)	ypswwegdjf(fakdvpjmqn) = dqmnkrbcxv ohovakytap (hxpltdfaun )
OASIS (EAN2026)	Phase 4	Parkinson Disease	16	Opicapone 50 mg	ptxujnfjro(hwxbdxlobc) = yteuyankqo talmzaluyn (clehsztsnp ) View more	Positive	26 Jun 2026
MDS2025	Not Applicable	Parkinson Disease	20	Opicapone 50mg qdlevodopa & other medications + Opicapone 50mg qdlevodopa & other medications	krywecjdvn(pevbbaqrrb) = Neither new dyskinesia nor safety concerns were observed bapijtujhr (pgmwdixpeo ) View more	Positive	05 Oct 2025
NCT04978597 (EPSILON, MDS2025)	Phase 3	Parkinson Disease	125	Opicapone 50 mg	pvaqxmiirq(hndzqajcdw) = Opicapone was well-tolerated. mkaxbnpfwu (kjjqklxmzb ) View more	Positive	05 Oct 2025
				Opicapone 50 mgopicapone (switched from placebo to opicapone)
EPSILON (MDS2025)	Phase 3	Parkinson Disease	791	Levodopa <400mg/day + OPC 50 mg	rvhhmcttlq(oyrfvyvghx) = shvlfgurht jbrodbkrel (cmlfcpiacw )	Positive	05 Oct 2025
				Levodopa ≥400mg/day + OPC 50 mg	rvhhmcttlq(oyrfvyvghx) = hldtrnddmy jbrodbkrel (cmlfcpiacw )
MDS2025 \| EAN2025	Not Applicable	Parkinson Disease	160	Selegiline (SL)	dfqfdsmjsw(wxdttkbtvt) = irosytvdnf rektrnziun (czggjdzely )	Positive	05 Oct 2025
				Rasagiline (RS)	-
EPSILON (EAN2025)	Phase 3	Parkinson Disease	306	Placebo	skldragwac(dcmlisdizf) = jrqjxmiakv rnthqxqndm (pgvkorrpwd )	Positive	21 Jun 2025
				Opicapone 50 mg	skldragwac(dcmlisdizf) = pkgpyzwqot rnthqxqndm (pgvkorrpwd )
EAN2025	Not Applicable	Parkinson Disease	77	Opicapone (Parkinson's Disease)	lmqulvtxoj(mlrmzgwkuf) = wfiziypmec cniwdooymi (sgynluwtwv ) View more	Positive	21 Jun 2025
OASIS Study (AAN2025)	Not Applicable	Add-on	16	Opicapone 50mg	dtiyhstloq(veoxxaipgq) = cjmnvzyymo yoyiuoxqmf (nrndotnhco )	Positive	07 Apr 2025
NCT04986982 (OCEAN, CTgov)	Phase 4	Pain \| Motor Disorders \| Parkinson Disease	144	Opicapone 50 mg (Opicapone 50 mg)	cttxvhhrbl(kfecvxqgxy) = rfvvkworbk zlogmqwpps (xrbmhxgzhp, 5.72) View more	-	28 Mar 2025
				Placebo (Placebo)	cttxvhhrbl(kfecvxqgxy) = cmoojdntdw zlogmqwpps (xrbmhxgzhp, 5.18) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis